Many applicants struggle to assemble CTD modules correctly — even small mistakes like missing or misplaced data in the dossier often leads to delays or outright rejection. If you’ve ever felt overwhelmed trying to organize complex documentation, it can feel like you’re navigating a minefield of regulations and formatting rules. This article explains how mastering eCTD modules can streamline the process, reduce errors and significantly increase the chances of a smooth regulatory submission.

How are the five CTD modules structured and what purpose does each serve?

The global regulatory framework for drug submissions — especially in the context of regulatory affairs — relies heavily on a consistent dossier format. The CTD modules provide exactly that: a harmonized structure to organize all necessary documentation for a marketing-authorization application.

There are five modules:

• Module 1: Administrative and regional information — forms, labeling, applicant and regional-specific documentation. This module is region-specific and will vary depending on the target regulatory authority.
• Module 2: Summaries and overviews — a digest of the key elements from Quality, Non-clinical and Clinical data. It includes an introduction, a “Quality Overall Summary,” a non-clinical overview, a clinical overview, plus written and tabulated summaries. It provides a high-level synthesis that helps regulators quickly understand the key evidence and rationale before delving into detailed modules.
• Module 3: Quality module — science and documentation around Chemistry, Manufacturing and Controls (CMC), pharmaceutical formulation, manufacturing processes, stability, specifications for drug substance and drug product, etc. This module demonstrates that the drug can be consistently produced with the required quality.
• Module 4: Non-clinical (preclinical) data — pharmacology, toxicology, pharmacokinetics/ADME, safety in animal models or in vitro, and all data that support safety before human trials.
• Module 5: Clinical data — human clinical study reports, efficacy and safety data from trials, statistical analyses, literature etc., supporting that the drug works and is safe in humans.

This modular structure allows companies and regulators to maintain clarity, consistency and global harmonization: core scientific information (modules 2–5) remains common across regions, while administrative/regional details are localized in Module 1.

What changes when CTD modules are submitted electronically as eCTD modules?

In modern regulatory submissions, paper-based dossiers are increasingly replaced with electronic submissions: eCTD modules. This transition transforms how dossiers are compiled, submitted and reviewed — and can significantly optimize the process. As part of Billev Pharma East’s services for regulatory submissions, leveraging the eCTD format is essential to meet contemporary regulatory expectations.

With an eCTD submission:

• All modules (1 through 5) retain the same content and logical structure as CTD — so the core scientific data and summaries remain the same. The difference lies in how everything is delivered: instead of bulky paper files, documents are organised in a predefined directory structure, accompanied by an XML “backbone” that defines metadata (file role, module, sequence, relationship).
• This structure standardizes submission across regions — Module 1 stays region-specific as always, while Modules 2–5 remain common. The eCTD format keeps everything in one consistent electronic dossier, facilitating global submissions.
• eCTD enables “lifecycle management”: once the initial dossier (sequence 0000) is submitted, any future update — new data, reports, variations — can be submitted as a new sequence (0001, 0002, …). The XML backbone tracks whether files are new, replaced, appended or deleted, preserving history and ensuring traceability across the product’s lifecycle
• For companies such as ours, eCTD reduces paper handling, simplifies dossier assembly, supports version control and archive, and dramatically improves submission efficiency. It also helps regulators review faster, since navigation becomes digital and structured from the start

Thus, while the content of the modules doesn’t change, the submission format does — and eCTD format makes the entire process faster, cleaner, and easier to manage.

Which documents belong in each module and why does proper placement matter for approval?

In the framework of CTD modules, every document included in a regulatory dossier must be placed into the correct module. If the dossier is to be accepted, that proper placement is not optional — it ensures clarity, prevents redundancy and supports a faster, smoother regulatory review. Module 3 is reserved for all data on quality: chemistry, manufacturing, controls, formulation, stability, and analytics. Module 4 collects non-clinical study reports: pharmacology, toxicology, pharmacokinetics, ADME, preclinical safety studies — in other words, evidence relevant to safety before human use. Module 5 is dedicated to clinical data, including study reports, statistical analyses, clinical safety and efficacy results, trial design and outcomes, plus literature references that strengthen the overall evidence package.. Module 2 serves as a “gateway”: it provides summaries and overviews (Quality Overall Summary, non-clinical and clinical overviews) that clearly connect the key messages fromthe detailed data in modules 3, 4 and 5. Finally, Module 1 contains administrative and region-specific documentation. When documents are misallocated — for example, quality data put into clinical modules or non-clinical reports placed into quality — the dossier becomes confusing, inconsistent or incomplete at first glance. Such errors often trigger regulatory queries or even rejection and can cost valuable time in the review cycle. Regulatory guidelines such as those from International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) define strict rules for content and placement, exactly to avoid those pitfalls. Ensuring that each document lands in the right module is therefore essential for a clean, reviewable, and compliant dossier that inspires confidence from the first review.

Module 3: what belongs here — drug substance & drug product CMC data

In the context of regulatory dossiers, Module 3 is where you compile all Chemistry, Manufacturing, and Controls (CMC) data for both the active substance (API) and the final medicinal product. This includes a comprehensive description of the drug substance (its chemical identity, structure, physical/chemical properties), details of its manufacture (synthetic route, process controls, material controls, impurity profiles, reference standards, stability data) as well as analogous information for the finished drug product (formulation, excipients, manufacturing process, quality controls, container-closure system, batch analyses, stability, etc.).

This quality documentation is the cornerstone that proves to regulators that the product can be consistently manufactured with defined specifications, ensuring safety, purity and reproducibility from batch to batch.

Because Module 3 data often constitute the majority of the dossier’s technical content, meticulous structure, clarity and completeness here directly influence regulatory acceptance — missing or inconsistent CMC data is one of the most common causes for requests for clarification or outright rejection during validation and scientific assessment.

How do eCTD modules improve navigation and reviewer efficiency compared to CTD?

With eCTD modules, the entire dossier is organised in a digital, standardized way that makes it far easier to access, review and manage information.. Rather than a jumble of paper files or loosely organized PDFs, the eCTD format imposes a strict directory structure (m1 through m5), and pairs content documents with a machine-readable XML backbone that defines metadata, file relationships and version history. That makes it much easier for reviewers to locate specific documents quickly — they can go directly to the relevant module, find the right file, check metadata (when it was uploaded, which sequence, whether it’s new or replaced) and understand the context at a glance. This electronic structure reduces the risk of misfiled documents, missed pages or lost appendices. Because the format merges content and metadata, it supports programmatic validation and consistency checks, which further reduces errors compared with manual, paper-based review. The result: review cycles become faster, more transparent and more efficient. Regulators and applicants alike benefit from clearer dossier navigation, better traceability and reduced administrative burden. Many national authorities now mandate or strongly prefer the eCTD format for submissions — making use of eCTD modules a practical necessity as well as a strategic advantage.

What common submission errors occur within CTD modules and how can they be avoided?

Even when using a structured format like CTD modules, mistakes are common — they often stem from misunderstanding module boundaries, weak internal organization, or inconsistent documentation practices. Common pitfalls include misplacing documents (for example, putting manufacturing data in a clinical module, or preclinical reports in the quality section), omitting key elements (such as stability data or control methods in the quality module), or providing incomplete summaries in Module 2 that fail to clearly reflect critical information from Modules 3, 4, or 5. Another frequent error relates to region-specific requirements: if Module 1 is not tailored correctly to local authority demands (e.g., forms, labeling, regional data), the entire submission may be rejected before even reaching technical review. In an eCTD context, technical mistakes (wrong directory names, missing XML backbone, incorrect pagination or metadata) can likewise derail the process. Avoiding such errors demands strict adherence to the ICH guidelines (such as M4), rigorous internal review and a disciplined documentation workflow. Each document should be mapped carefully to the correct module, summaries must faithfully reflect the underlying data, and all administrative/regional information must be validated against target-region requirements. Internal checklists, thorough quality control and, for eCTD, using validated submission tools can greatly reduce risk of errors and prevent avoidable delays.

Module 5: clinical study reports — the evidence base for efficacy and safety

Within the framework of CTD modules, Module 5 is the section dedicated entirely to presenting all human clinical data collected during drug development. This includes full clinical study reports (CSRs), data from pharmacokinetic/pharmacodynamic studies, biopharmaceutic or bioequivalence studies (if applicable), as well as post-marketing experience, if included. The primary objective of Module 5 is to provide regulators with the concrete evidence needed to evaluate the benefit–risk profile of the investigated medicinal product. Through detailed trial results, safety and efficacy data, statistical analyses, and patient-level information (where required), Module 5 allows regulatory authorities to verify that the product performs as intended and meets standards of safety and effectiveness. The module is structured so that it starts with a Table of Contents (5.1) for ease of navigation. This is followed by a tabular listing of all clinical studies (5.2), which gives an overview of what trials have been conducted, their phase, objectives, population, and status — helping reviewers quickly assess the scope of the clinical program before moving into the full reports. . Afterwards, the bulk of the module comprises the clinical study reports themselves (5.3). These are typically organised into sub-sections (e.g. biopharmaceutic studies, pharmacokinetics/pharmacodynamics studies, efficacy and safety trials, and possibly post-marketing data), depending on the product and development program. Finally, Module 5 includes literature references or published studies (5.4) that support or complement the clinical data submitted — for example, long-term follow-up studies or epidemiological data if relevant to strengthen the overall evidence package.

In sum, Module 5 forms the evidentiary backbone of any regulatory submission for a new medicine, as it delivers the human data needed for final regulatory decisions on efficacy and safety.

How does lifecycle management work across eCTD modules during updates and variations?

One of the strongest advantages of eCTD modules is their built-in support for lifecycle management — crucial for managing updates, variations or post-approval changes over time. Once an initial dossier (sequence “0000”) is submitted, any subsequent changes — such as updated stability data, new non-clinical or clinical findings, manufacturing process modifications — can be submitted as incremental updates in new sequences (0001, 0002, …). The XML backbone tracks the status of each file: new, replaced, appended or deleted — preserving history while making it immediately clear what changed.. This approach avoids the need to resubmit the entire dossier each time. Regulators can easily see which documents are new or modified, making review more efficient and transparent. From the sponsor’s perspective, this modular update capability reduces workload, lowers the  risk of omissions, and simplifies regulatory maintenance. For products with long life cycles or frequent changes, eCTD lifecycle management therefore becomes a major operational benefit — supporting faster updates without compromising compliance or traceability.

Why is understanding module interdependencies essential for building a compliant dossier?

Although each module of the CTD modules framework has a distinct role, they are deeply interconnected — and successful dossier preparation requires a clear understanding of these interdependencies. The overviews in Module 2, for example, depend directly on the detailed data contained in Modules 3, 4 and 5; if those underlying data are weak, incomplete or inconsistent, the summaries become unreliable or misleading and invite avoidable questions. Similarly, modifications in manufacturing processes or quality control (Module 3) may impact safety or efficacy, necessitating updates in non-clinical (Module 4) or clinical data (Module 5). Ignoring these links may result in discrepancies, regulatory objections or even rejection at validation or during assessment. Effective dossier preparation therefore demands a holistic approach: modules should not be treated in isolation, but developed in parallel with cross-referencing, consistency checks and a consistent, end-to-end documentation flow across modules. Only with a well-synchronized, interdependent structure can a dossier reflect true quality, safety and efficacy — and meet the expectations of regulators.

Read also:

• What are the key steps in effective eCTD lifecycle management?
• How can regulatory outsourcing optimise your RA resource allocation?
• How can a regulatory strategy improve the efficiency of your approval pathway?

Sources: 1 – International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2004). M4: Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (R4), 2 – European Medicines Agency (EMA). (n.d.). ICH M4 Common technical document (CTD) for the registration of pharmaceuticals for human use – organisation of CTD – Scientific guideline, 3 – Therapeutic Goods Administration (TGA). (2014). Understanding the Common Technical Document (CTD), 4 – PSC Biotech / Biotech.com. (2022, October 24). Difference between CTD and eCTD Submission Formats, 5 – m-Pharmainfo.com. (2025, June). CTD vs. eCTD Submission Formats, 6 – Alchemy Medical Writing. (n.d.). Overview of Common Technical Documents.

Image credits:

In-article image: Photo by Markus Spiske by Unsplash

Hero image: Photo by Mohamed Marey by Unsplash